Victory Capital Management
PRVL

Victory Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Victory Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,496
Closed -$116K – 3646
2020
Q1 		$116K Buy
+9,496
New +$151K ﹤0.01% 2499
2019
Q4 		– Sell
-1,343
Closed -$16K – 3620
2019
Q3 		$16K Buy
+1,343
New +$15.2K ﹤0.01% 3128

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Victory Capital Management's PRVL Position: Q2 2020 in Review

Victory Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q2 2020, closing a stake of 9,496 shares — an estimated $116K sold.

Victory Capital Management first reported a position in PRVL in Q3 2019 and held it in 2 quarters. The position peaked at $116K in Q1 2020. 67 funds tracked by Wall St. Rank hold PRVL as of Q2 2020.

  • Victory Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 9,496 Prevail Therapeutics Inc. Common Stock shares in Q2 2020, an estimated $116K.
  • Victory Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $116K in Q1 2020.
  • 67 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.